 |
 |

2-Adrenergic Receptor Genotype and Survival After Acute Coronary Syndrome
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: The study by Dr Lanfear and colleagues1 showed an apparent disconnect between the effects that ADRB2 and ADRB1 variants have on survival in patients receiving -blockers after an acute coronary syndrome. The homozygous composite genotypes comprising Arg-Arg16 /Gln-Gln 27 (46AA/79CC) and Gly-Gly16/Glu-Glu 27 (46GG/79GG) were associated with a higher and lower risk of death, respectively, amounting to a 14% difference in mortality rate over 3 years.
The acute fall in serum potassium level and diastolic blood pressure in response to ADRB2 stimulation by albuterol is significantly greater in patients with genotype 46AA/79CC compared with 46GG/79GG.2 This suggests the possibility of a genetic susceptibility to the ADRB2-mediated adverse effects of raised levels of endogenous circulating epinephrine in the high-risk group when treated with -blockers.
The authors did not state which -blockers were used in the study. This is relevant because the more commonly used 1-selective blockers might . . . [Full Text of this Article]
Catherine M. Jackson, MD
Tayside Centre for General Practice
Brian J. Lipworth, MD
b.j.lipworth@dundee.ac.uk Division of Medicine and Clinical Pharmacology Ninewells Hospital and Medical School Dundee, Scotland
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
2-Adrenergic Receptor Genotype and Survival After Acute Coronary Syndrome
Eric M. Snyder and Bruce D. Johnson
JAMA. 2006;295(7):756-757.
EXTRACT
| FULL TEXT
2-Adrenergic Receptor Genotype and Survival After Acute Coronary SyndromeReply
David E. Lanfear, John A. Spertus, and Howard L. McLeod
JAMA. 2006;295(7):757-758.
EXTRACT
| FULL TEXT
2-Adrenergic Receptor Genotype and Survival Among Patients Receiving -Blocker Therapy After an Acute Coronary Syndrome
David E. Lanfear, Philip G. Jones, Sharon Marsh, Sharon Cresci, Howard L. McLeod, and John A. Spertus
JAMA. 2005;294(12):1526-1533.
ABSTRACT
| FULL TEXT
|